SCHEMBL4033307

SCHEMBL4033307

Cc1ccc([C@H]2CCCN(C(=O)OCc3ccc(C(F)(F)F)cc3)C2)cc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
BCL9 O00512 10/20 0.54
CTNNB1 P35222 10/20 0.54
PDE4B Q07343 2/20 0.45
PROKR1 Q8TCW9 2/20 0.45
LIPG Q9Y5X9 1/20 0.41
CETP P11597 1/20 0.41
MYC P01106 1/20 0.41
GPBAR1 Q8TDU6 1/20 0.40
RORC P51449 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4028580 1.00 BCL9 (0.54) BCL9CTNNB1PDE4BPROKR1LIPG
SCHEMBL4028589 1.00 BCL9 (0.54) BCL9CTNNB1PDE4BPROKR1LIPG
SCHEMBL6193937 0.95 BCL9 (0.50) BCL9CTNNB1PDE4BPROKR1LIPG
SCHEMBL6193930 0.95 BCL9 (0.50) BCL9CTNNB1PDE4BPROKR1LIPG
SCHEMBL4030825 0.93 BCL9 (0.54) BCL9CTNNB1PDE4BPROKR1LIPG
SCHEMBL4029539 0.91 BCL9 (0.47) BCL9CTNNB1PDE4BPROKR1MYC
SCHEMBL4034960 0.91 BCL9 (0.47) BCL9CTNNB1PDE4BPROKR1MYC
SCHEMBL4029545 0.91 BCL9 (0.47) BCL9CTNNB1PDE4BPROKR1MYC
SCHEMBL4034468 0.91 BCL9 (0.51) BCL9CTNNB1PDE4BPROKR1CETP
SCHEMBL4034464 0.91 BCL9 (0.51) BCL9CTNNB1PDE4BPROKR1CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1567493-B1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PROD INC (US) 2009-03-18 EP claimed
CN-100439337-C Phenyl substituted piperidine compounds for use as PPAR activators PFIZER PROD INC (US) 2008-12-03 CN claimed
US-20070191429-A1 PPAR ACTIVATORS PFIZER INC. (US) 2007-08-16 US claimed
US-7199243-B2 Piperidine compounds useful as PPAR activators PFIZER INC. (US) 2007-04-03 US claimed
CN-1717389-A Phenyl substituted piperidine compounds for use as PPAR activators PFIZER PROD INC (US) 2006-01-04 CN claimed
EP-1567493-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS Pfizer Products Inc. (US) 2005-08-31 EP claimed
US-20040157885-A1 PPAR activators PFIZER INC 2004-08-12 US claimed
WO-2004048334-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PRODUCTS INC. (US) 2004-06-10 WO claimed
EP-1567493-B1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PROD INC (US) 2009-03-18 EP disclosed
CN-100439337-C Phenyl substituted piperidine compounds for use as PPAR activators PFIZER PROD INC (US) 2008-12-03 CN disclosed
US-20070281935-A1 Use PFIZER INC. (US) 2007-12-06 US disclosed
US-20070232647-A1 Use of Ppar Agonists to Treat Ruminants GOETZE LEOPOLD F 2007-10-04 US disclosed
US-20070191429-A1 PPAR ACTIVATORS PFIZER INC. (US) 2007-08-16 US disclosed
US-7199243-B2 Piperidine compounds useful as PPAR activators PFIZER INC. (US) 2007-04-03 US disclosed
CN-1717389-A Phenyl substituted piperidine compounds for use as PPAR activators PFIZER PROD INC (US) 2006-01-04 CN disclosed
WO-2005115369-A2 USE OF PPAR AGONISTS TO TREAT RUMINANTS PFIZER PRODUCTS INC. (US) 2005-12-08 WO disclosed
WO-2005115389-A2 SPECIFIC PPAR AGONISTS FOR TREATING NEGATIVE ENERGY BALANCE PFIZER PRODUCTS INC. (US) 2005-12-08 WO disclosed
EP-1567493-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS Pfizer Products Inc. (US) 2005-08-31 EP disclosed
US-20040157885-A1 PPAR activators PFIZER INC 2004-08-12 US disclosed
WO-2004048334-A1 PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS PFIZER PRODUCTS INC. (US) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191429-A1 PPAR ACTIVATORS PPARA, PPARG, PPARD BCL9 2684/4885CTNNB1 2280/4885PDE4B 615/4885
US-20040157885-A1 PPAR activators PPARA, PPARG, PPARD BCL9 2684/4885CTNNB1 2280/4885PDE4B 615/4885
US-20070281935-A1 Use ALPP, CPT1A, PIGS BCL9 3385/4885CTNNB1 995/4885PDE4B 4165/4885
US-20070232647-A1 Use of Ppar Agonists to Treat Ruminants PPARG, PPARD, PPARA BCL9 3397/4885CTNNB1 1557/4885PDE4B 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.